Integral Health Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Integral Health Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.73M	Buy	+200,000	New	+$2.91M	0.15%	79

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Integral Health Asset Management's TRVI Position: Q2 2026 in Review

Integral Health Asset Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 200,000 shares worth $3.73M. The stake represents 0.15% of the portfolio and ranks #79 among its holdings.

217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Integral Health Asset Management held 200,000 shares of Trevi Therapeutics worth $3.73M as of Q2 2026.
Trevi Therapeutics was a new Integral Health Asset Management position in Q2 2026.
Trevi Therapeutics made up 0.15% of Integral Health Asset Management's portfolio in Q2 2026, its #79 holding.
217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.